The Genetics Policy Institute and Future Medicine have announced the publication of this year's World Stem Cell Report as a supplement to the journal Regenerative Medicine. This coincides with the 2012 World Stem Cell Summit, for which scientists, policymakers and advocates from around the world have come together to Florida.
The Summit is said to bring together some of the world's brightest minds, working together to translate stem cell research into cures. In order to extend and capitalise on that knowledge, the Genetics Policy Institute publishes an annual snapshot of the field – the World Stem Cell Report – released at the World Stem Cell Summit each year.
After the success of last year's collaboration, the World Stem Cell Report is again being published as a supplement to the peer-reviewed Regenerative Medicine. It is seen to benefit from the journal's high standards in content and presentation, including rigorous peer review, indexing on MEDLINE, Scopus and ISI, and full colour illustrations throughout.
The theme of this year's World Stem Cell Report focuses on a key goal of both the World Stem Cell Summit and Regenerative Medicine: 'Closing the translational gap' between the lab and the clinic to bring new therapies to patients safely and efficiently. With that goal in mind, the senior editor of Regenerative Medicine, Prof. Chris Mason, and executive director of the Genetics Policy Institute, Bernard Siegel, have chosen a range of topics to reflect the cutting edge of stem cells and regenerative medicine, from preclinical research to the latest clinical trials.
The highlights of the summit include: research updates from top scientists give accessible overviews on the current state of research in their field, including Camillo Ricordi (University of Miami) and Roger Barker (University of Cambridge); Martin McGlynn, President and CEO of one of the most talked about stem cell companies of the year, Stem Cells, Inc., shares the latest news from their clinical trials. The summit also includes Todd McAllister (Cytograft) and Gil van Bokkelen (Athersys/Alliance for Regenerative Medicine) giving their differing views on a topic that has caused much controversy this year: regulation of autologous stem cell therapies; and a series of global updates, highlighting the key researchers and institutions in countries around the world, this year featuring the US, Canada, the UK, Sweden and Brazil.
